Cell‐Active, Arginine‐Targeting Irreversible Covalent Inhibitors for Non‐Kinases and Kinases

Authors:
Publisher website
Google Scholar
Abstract
Targeted covalent inhibitors (TCIs) play an essential role in the fields of kinase research and drug discovery. TCI strategies to target more common amino acid side‐chains have yet to be demonstrated. Targeting other amino acids would also expand the pharmaceutical industry‘s toolbox for targeting other tough‐to‐drug proteins. We report herein a glyoxal‐based, arginine‐reactive strategy to generate potent and selective small‐molecule TCIs of Mcl‐1 (an important anti‐apoptotic protein) by selectively targeting the conserved arginine (R263) in the protein. We further validated the generality of this strategy by developing glyoxal‐based, irreversible covalent inhibitors of AURKA (a cancer‐related kinase) that showed exclusive reactivity with a solvent‐exposed arginine (R220) of this enzyme. We showed the resulting compounds were potent, selective and cell‐active, capable of covalently engaging endogenous AURKA in MV‐4–11 cells with long residence time. Finally, we showed the potential application of glyoxal‐based TCIs in targeting an acquired drug‐resistance mutant of ALK kinase (G1202R).
Funding Information
  • National Natural Science Foundation of China (32171184)
  • Basic and Applied Basic Research Foundation of Guangdong Province (2023B0303000026)
  • Natural Science Foundation of Guangdong Province (2023A1515012763)
  • Special Funds for the Basic Research and Development Program in the Central Non-profit Research Institutesof China (2022YFA1104800)

This publication has 50 references indexed in Scilit: